If retatrutide follows the same pattern, we would expect an Eli Lilly regulatory filing in late 2026, MHRA approval in late 2027 to mid-2028, and NHS access through NICE from 2029 at the earliest
Semaglutide can cause skin sensitivity in some users, though it is not the most common side effect
Lipolysis upregulation: Enhances adipose tissue breakdown independent of caloric restriction
So Part D is still central to the Bridge as an eligibility requirement, even though the plan-based BALANCE coverage is not happening for now
While their glucose-lowering effects have been well documented for years, recent clinical breakthroughs have shown that these medications can deliver transformative weight loss, often rivalling or even surpassing results from bariatric surgery for certain patients
Usually only one eye is affected